Navigation Links
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
Date:2/10/2009

-Cohort 1 Data Promising for Type 2 Diabetes-

PLYMOUTH MEETING, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. Mr. Jack Armstrong, President and CEO of Genaera, presented data from the first of three cohorts in an ascending multiple dose study of MSI-1436 (Study 102), during the BIO CEO & Investor Conference in New York.

Data from cohort 1, in which eight doses of 3 mg/m2 of MSI-1436 were administered over 21 days to overweight and obese type 2 diabetic subjects, demonstrated meaningful improvement in four primary outcomes used to evaluate type 2 diabetes, including:

  • A 9.5% decrease in fasting blood glucose with a resulting 17% differential compared to placebo subjects in the same cohort;
  • A 7% decrease in the area under the curve during the oral glucose tolerance test;
  • An 11.3% decrease in serum fructosamine, which is used to monitor short-term (2-3 weeks) blood sugar control; and
  • A 0.4% decrease in hemoglobin A1C (HbA1C), used to monitor longer-term (2-3 months) blood sugar control.

"It is very exciting to see a believable biologic response to MSI-1436 in cohort 1 of Study 102. While 3 mg/m2 of drug was thought to be a sub-therapeutic dose, the data has demonstrated otherwise. We are currently completing the in-house portion of the second cohort of this study evaluating 6 mg/m2 of MSI-1436 and the initial results support proceeding to the 10 mg/m2 cohort which will begin later this month. Final Study 102 data is expected in the second quarter," comme
'/>"/>

SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
2. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
3. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
6. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
7. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
8. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
10. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
11. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014  Over 200 patients, families, physicians ... to learn, interact and participate in the drive ... Lupus Trials Fair launched by the Lupus ... Lupus Foundation .  Attendees interacted directly with researchers ... experiences, ideas and needs and learning about more ...
(Date:9/15/2014)... 2014 Biomerics LLC, a leading provider ... announced its merger with Access Point Technologies and ... division was formed to provide next generation catheter ... structure heart, interventional radiology, interventional cardiology, and neurovascular ... will be led by Steve Berhow , ...
(Date:9/15/2014)... 2014 Chek Diagnostics, the U.S.-based manufacturer of ... point-of-care diagnostic products, has again been named to the ... companies in America. The Inc. 5000 ranking ... Chek Diagnostics earned its place on the list by ... 2013. For Chek Diagnostics, who appears on ...
Breaking Medicine Technology:Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3Biomerics and Access Point Technologies OEM Announce Merger and Creation of Biomerics Advanced Catheter Division 2Chek Diagnostics Named to Inc. Magazine's 5000 Fastest Growing Private Companies List for the Fourth Time 2Chek Diagnostics Named to Inc. Magazine's 5000 Fastest Growing Private Companies List for the Fourth Time 3
(Date:9/15/2014)... News) -- Births of multiple babies cost more and ... births, researchers report. The researchers suggest that limiting ... could ease some of that burden. Over the ... with births to older mothers and use of assisted ... New South Wales, Australia. Their study, published online ...
(Date:9/15/2014)... 15, 2014 As Colorado's historic ... its first full year, there are a variety ... in the evolution of its marketing and branding. ... taken by Denver's Kindman, one of the state's ... , Kindman has pioneered the first-ever branded and ...
(Date:9/15/2014)... September 15, 2014 According to a ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... was valued at USD 12,212.9 million in 2013 and ... at a CAGR of 7.2% from 2014 to 2020. ... properties of light within specific electromagnetic spectrum to identify ...
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... in U.S. courts, Bernstein Liebhard LLP notes that a ... be useful in curbing aggression in children with ADHD ... and parent training in behavioral management techniques. According to ... children with ADHD and aggression problems, half of whom ...
(Date:9/15/2014)... Adding chest radiation to chemotherapy allows some people with ... rates by nearly 50 percent, European researchers report. ... researchers recommended that chest radiotherapy be routinely offered to ... chemotherapy. , , Small-cell lung cancer (SCLC) is an ... 13 percent of all lung cancers. For most people, ...
Breaking Medicine News(10 mins):Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 2Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 4Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 5Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 2Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 3
... finds these doctors have better results, including survival rates ... surgeons may be the best choice for adults requiring ... study suggests. , A congenital heart defect occurs when ... vessels near the heart. , The researchers analyzed a ...
... researchers from,Wayne State University, in collaboration with Basrah Medical ... New Iraqi Journal of,Medicine today on war-related mental health ... Bengt B. Arnetz, Ph.D., professor of Family Medicine and ... State University led the team,of researchers to conduct a ...
... cardiac valves years later , , FRIDAY, Nov. 7 (HealthDay News) ... help fight obesity has been tied to heart value damage ... a new study reports. , The appetite suppressant fenfluramine ... of its links to heart damage. Thousands of lawsuits have ...
... Triple-S,Management Corporation (NYSE: GTS ) today ... Officer, and Juan-Jose Roman,Finance Vice President & CFO, ... Credit Suisse 2008 Healthcare Conference in Phoenix on,November ... presentation will be,broadcast live through the Internet. You ...
... by a tumor or injury carry a severe psychological and ... in plastic surgery. Helmut Fischer and Wolfgang Gubisch present the ... of Deutsches rzteblatt International ( Dtsch Arztebl Int ... a woman who had had a tumor removed from the ...
... Events Held in Los Angeles Area Enable Medicare,Beneficiaries ... Period, SAN FRANCISCO, Nov. 7 Helping ... of California is offering,free "Fitness and Flexibility" events ... month. The events will offer a demonstration of ...
Cached Medicine News:Health News:Pediatric Heart Surgeons May Be Best Choice for Adults 2Health News:First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq 2Health News:Banned Obesity Drug Tied to Heart Risks Long After Use 2Health News:Triple-S Management Corporation to Present at Credit Suisse 2008 Healthcare Conference 2Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 2Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 3Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 4Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 5
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
The unique MR-frame and its indicators are made of a highly tensile and fibre reenforced Epoxyd material....
VG2 PLIF (Parallel) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit cor...
An all-cortical structure provides the structural benefits of cortical bone. Precision machined to exact specifications to promote healthy lordosis and vertebral body distraction....
Medicine Products: